Eileen E. Ming founded Epi Excellence LLC, an epidemiology consulting company, following an extensive record of success as an epidemiologist, pharmacoepidemiologist, outcomes researcher, and leader in the pharmaceutical industry. Before starting in consulting, she was the head of the global epidemiology/pharmacoepidemiology function at Shire Pharmaceuticals, primarily focused on neurosciences, GI, and rare diseases. Previously, she held positions of increasing responsibility and influence at Merck and AstraZeneca, where she was the lead epidemiologist for 3 major brands, the US therapeutic area lead for CV/metabolic, and the global therapeutic area lead for neuroscience.
Eileen has worked across a variety of therapeutic areas, from pre-clinical to post-marketing phases, providing epidemiologic strategic and tactical expertise to support local and global commercial, clinical, pharmacovigilance, and regulatory activities. Achievements include successfully negotiating face-to-face with FDA to allow a pharmacoepi database study to replace a requested randomized clinical trial in an NDA package.
Eileen is also an Adjunct Scholar of the Center for Clinical Epidemiology and Biostatistics, and an Adjunct Investigator of the Center for Pharmacoepidemiology Research and Training, at the Perelman School of Medicine at the University of Pennsylvania. She has been named a Fellow of the International Society for Pharmacoepidemiology.
Eileen received her epidemiology training at the Harvard School of Public Health (ScD in Epidemiology, concentration in Psychiatric Epidemiology, minors in Biostatistics, and Health and Social Behavior) and the Johns Hopkins Bloomberg School of Public Health (MPH). She earned her undergraduate degree in Human Biology from Stanford University.
Eileen has worked across a variety of therapeutic areas, from pre-clinical to post-marketing phases, providing epidemiologic strategic and tactical expertise to support local and global commercial, clinical, pharmacovigilance, and regulatory activities. Achievements include successfully negotiating face-to-face with FDA to allow a pharmacoepi database study to replace a requested randomized clinical trial in an NDA package.
Eileen is also an Adjunct Scholar of the Center for Clinical Epidemiology and Biostatistics, and an Adjunct Investigator of the Center for Pharmacoepidemiology Research and Training, at the Perelman School of Medicine at the University of Pennsylvania. She has been named a Fellow of the International Society for Pharmacoepidemiology.
Eileen received her epidemiology training at the Harvard School of Public Health (ScD in Epidemiology, concentration in Psychiatric Epidemiology, minors in Biostatistics, and Health and Social Behavior) and the Johns Hopkins Bloomberg School of Public Health (MPH). She earned her undergraduate degree in Human Biology from Stanford University.
Epi Excellence LLC personnel includes 35+ epidemiologists, biostatisticians, health economists, and other scientists, located globally. Their varied experience includes being a staff epidemiologist at a pharmaceutical company or epidemiology service provider, health program implementation and evaluation, public health epidemiology, qualitative research, and clinical research. All epidemiologists have a masters or doctorate degree in epidemiology, biostatistics, or public health. Additional resources include physician-researchers, specialist epidemiologists, medical librarians, and programmers.
Epi Excellence LLC is proud to be a certified National Women's Business Enterprise (NWBE) and a certified Minority Business Enterprise (MBE), as well as having been named one of the 100 fastest growing privately-held companies in the Philadelphia region for two years in a row (2021, 2022) by the Philadelphia 100 Forum.
|
|
|
|
|
|
|
|
+1 (610) 497-8918 info@epiexcellence.com